| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Collins Helen Louise is a Chief Medical Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 7 sells.
Estimated insider holdings value: $1.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 5,000 | $47.67 | $238,352.42 | -5.7% | - | - | |
| Mar 10, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 40,000 | $30.07 | $1,202,637.98 | -44.4% | - | - | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 816 | $30.00 | $24,482.45 | -100% | -24.2% | -26.2% | |
| Apr 11, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 20,000 | $25.07 | $501,478.00 | -100% | -3.2% | -30.7% |